Supplementary Online Content
|
|
- Lora Hood
- 6 years ago
- Views:
Transcription
1 Supplementary Online Content Åsvold BO, Vatten LJ, Bjøro T, et al; Thyroid Studies Collaboration. Thyroid function within the normal range and risk of coronary heart disease: an individual participant data analysis of 14 cohorts. JAMA Intern Med. Published online April 20, doi: /jamainternmed etable 1. Information on FT 4 and TPO Antibody Measurements and Types of CHD Event Data Available in Each Cohort etable 2. Baseline Characteristics by Thyrotropin Category etable 3. Sensitivity Analyses of the Association of Thyrotropin With Risk of CHD Outcomes etable 4. s of CHD Outcomes by Combinations of Thyrotropin Level and TPO Antibody Status at Baseline etable 5. s of CHD Outcomes per 1 pmol/l Higher FT 4 Level at Baseline, Overall and by Sex and Age etable 6. s of CHD Outcomes by Quartile Categories (Q) of FT 4 Levels at Baseline, Overall and by Sex and Age at Baseline etable 7. Sensitivity Analyses of the Association of FT 4 With Risk of CHD Outcomes etable 8. Sensitivity Analyses of the Association of FT 4 Quartile Categories With Risk of CHD Outcomes efigure. Hazard Ratios (s) of Coronary Heart Disease (CHD) Mortality, a First-Time CHD Event and a First-Time Hard CHD Event per 1 pmol/l Higher Free Thyroxine (FT 4 ) Level at Baseline, Adjusted for Age, Sex and Smoking at Baseline This supplementary material has been provided by the authors to give readers additional information about their work American Medical Association. All rights reserved. 1
2 etable 1. Information on FT 4 and TPO antibody measurements and types of CHD event data available in each cohort. Cohort FT 4 reference range CHD mortality methods for ascertainment Incident fatal and nonfatal CHD events - definitions TPO antibody measurement; a criteria for positive test Europe Whickham Survey NA NA Death certificates, postmortem reports, hospital or general practitioners reports, ECG during the final recorded illness; causes of death coded with ICD Rotterdam Study pmol/l c Leiden 85-Plus Study pmol/l Milenia, DPC; positive if >10 IU/mL NA Information from general practitioners and letters and discharge reports of medical specialists, coded independently by two study physicians and subsequently validated by a medical specialist (Leening MJ et al. Eur J Epidemiol 2012;27(3): ) Causes of death obtained from Statistics Netherlands, where all national death certificates are coded by experts; ICD-10 I20-I25 Fatal or non-fatal myocardial infarction, angina pectoris diagnosis by general practitioners, myocardial infarction on ECG, death certificates. CHD mortality, nonfatal myocardial infarction, or coronary artery revascularization Fatal and non-fatal myocardial infarction, angina pectoris Incident fatal and non-fatal CHD events methods for ascertainment Self-reported history of angina or myocardial infarction confirmed by general practitioners or hospital records Information from general practitioners and letters and discharge reports of medical specialists, coded independently by two study physicians and subsequently validated by a medical specialist (Leening MJ et al. Eur J Epidemiol 2012;27(3): ) Interview, ECG and records of general practitioners Available data on incident hard CHD events b No Yes Yes 2015 American Medical Association. All rights reserved. 2
3 HUNT Study 8-20 pmol/l c NA Death certificates coded with ICD or ICD-10 I20-I25 EPIC-Norfolk Study 9-20 pmol/l NA Death certificates and hospital coding: causes of death coded with ICD-9- SHIP pmol/l PROSPER trial pmol/l InCHIANTI ng/dl United States Health, Aging, and Body Composition Study AutoDelfia, PerkinElmer Life and Analytical Sciences, Wallac Oy; positive if >200 IU/mL NA NA CM Death certificates from local health authority; independent validation of cause of death; review with another expert if disagreement; coded with ICD-10 I20-I25 Trial reviewed every 3 months Data from regional Mortality General Registry and death certificates at registry offices of the municipalities; ICD ng/dl c NA Hospital records, death certificates, and other support documents reviewed by a panel of clinicians CHD mortality or hospitalization with myocardial infarction CHD mortality or hospital coding with diagnosis of CHD (ICD-9-CM ) Linkage with national cause of death registry and hospital records Hospital discharge coding by data linkage with NHS central register Yes No NA NA No CHD mortality or nonfatal myocardial infarction CHD mortality, or hospitalization with CHD (ICD ), or myocardial infarction or angina pectoris recorded at follow-up visits after 3, 6, and 9 years Fatal or non-fatal acute myocardial infarction, angina pectoris, angioplasty of coronary arteries, or coronary artery Trial reviewed every 3 months Mortality General Registry and death certificates; hospital discharge coding; self-report, medication, documentation, ECG or Rose Angina Questionnaire score recorded at follow-up visits Interview, hospital records, and other support documents reviewed by a panel of clinicians Yes Yes Yes 2015 American Medical Association. All rights reserved. 3
4 Cardiovascular Health Study ng/dl MrOS ng/dl Australia Busselton Health Study Asia Nagasaki Adult Health Study South America Brazilian Thyroid Study Elecsys 2010, Roche Diagnostics; positive if >37 IU/mL NA 9-23 pmol/l Immulite 2000, Siemens; positive if 35 IU/mL ng/dl ng/dl NA AutoDelfia, PerkinElmer Life and Analytical Sciences, Wallac Oy; positive if 35 IU/mL Medical records, death certificates, autopsy reports, and coroners reports reviewed by experts Death certificates with ICD , adjudicated by a physician Registrar General s list of deaths: coded with ICD-9-CM Death certificates; causes of death coded with ICD-9- CM surgery Myocardial infarction, Interview and Yes angina pectoris, hospital records coronary angioplasty, reviewed by experts coronary artery surgery, atherosclerotic CHD mortality NA NA No CHD mortality or hospital coding with a diagnosis of CHD Hospital records: diagnoses coded with ICD-9 and ICD- 10 No NA NA No Death certificates NA NA No Abbreviations: CHD, coronary heart disease; ECG, electrocardiogram; FT 4, free thyroxine; ICD-9, International Classification of Diseases, Ninth Revision; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10, International Classification of Diseases, Tenth Revision; NA, data not available; NHS, National Health Service; TPO, thyroid peroxidase a Only reported for cohorts that measured TPO antibody levels in euthyroid. b CHD mortality and myocardial infarction c In these cohorts, FT 4 levels were not measured in people with thyrotropin within the reference range American Medical Association. All rights reserved. 4
5 etable 2. Baseline characteristics by thyrotropin category. Serum thyrotropin concentration at baseline (miu/l) Characteristics No. of 24,169 20, Age (years), mean (SD) 56.6 (14.3) 59.1 (13.6) 61.3 (13.2) 62.7 (13.1) Women, % Current smoking, % a Body mass index (kg/m 2 ), mean (SD) 26.2 (4.0) 26.5 (4.2) 26.5 (4.4) 26.3 (4.5) Diabetes, % Systolic blood pressure (mmhg), mean 138 (22) 140 (22) 141 (23) 142 (23) (SD) Total serum cholesterol (mg/dl), mean (SD) 231 (46) 234 (46) 232 (47) 232 (48) a Not including the from the Nagasaki Adult Health Study, which classified as ever or never smokers American Medical Association. All rights reserved. 5
6 etable 3. Sensitivity analyses of the association of thyrotropin with risk of CHD outcomes. s a of CHD outcomes per 1 miu/l higher thyrotropin level at baseline. CHD mortality CHD events Hard CHD events b No. events/ No. events/ No. events/ Main analysis 1808 / 54, ( ) 4666 / 48, ( ) 2488 / 34, ( ) Excluding the first 2 years of follow-up 1631 / 53, ( ) 3976 / 47, ( ) 2055 / 33, ( ) With adjustment for BMI 1769 / 54, ( ) 4590 / 48, ( ) 2445 / 34, ( ) Excluding with diabetes 1586 / 52, / 46, / 32, ( ) Restricted to never-smokers 708 / 24, ( ) Restricted to cohorts with information on thyroid medication during follow-up Including with 748 / 15, thyroid medication during follow-up ( ) Excluding with thyroid medication during follow-up Restricted to cohorts that were identified through the systematic literature searches 730 / 15, ( ) 1669 / 50, ( ) ( ) 1751 / 21, ( ) 1915 / 10, ( ) 1858 / 10, ( ) 4243 / 45, ( ) Excluding the SHIP cohort 1782 / 51, ( ) Excluding the Whickham Survey and 1656 / 52, / 46, the Leiden 85-Plus Study ( ) ( ) Abbreviations: BMI, body mass index; CHD, coronary heart disease; CI, confidence interval;, hazard ratio; NA, not applicable a adjusted for age, sex and smoking at baseline unless otherwise noted b CHD mortality or myocardial infarction ( ) 978 / 15, ( ) 975 / ( ) 935 / ( ) 2108 / 30, ( ) NA NA 2457 / 33, ( ) 2015 American Medical Association. All rights reserved. 6
7 etable 4. s a of CHD outcomes by combinations of thyrotropin level and TPO antibody status at baseline. Thyrotropin level TPO antibody No. events / 95% CI (miu/l) status CHD mortality Negative 299 / Reference Positive 20 / Negative 113 / Positive 14 / CHD events Negative 714 / Reference Positive 42 / Negative 249 / Positive 35 / Hard CHD events b Negative 373 / Reference Positive 19 / Negative 174 / Positive 25 / Abbreviations: CHD, coronary heart disease; CI, confidence interval;, hazard ratio; TPO, thyroid peroxidase a adjusted for age, sex and smoking at baseline b CHD mortality or myocardial infarction 2015 American Medical Association. All rights reserved. 7
8 etable 5. s a of CHD outcomes per 1 pmol/l higher FT 4 level at baseline, overall and by sex and age. CHD mortality CHD events Hard CHD events b No. events/ 95% CI No. events/ 95% CI No. events/ 95% CI Overall 931 / 23, / 18, / Sex Women 374 / 12, / / Men 557 / 11, / / P interaction Age at baseline <65 years 125 / 13, / / years 660 / / / years 146 / / / P trend Abbreviations: CHD, coronary heart disease; CI, confidence interval; FT 4, free thyroxine;, hazard ratio a adjusted for age, sex and smoking at baseline b CHD mortality or myocardial infarction 2015 American Medical Association. All rights reserved. 8
9 etable 6. s a of CHD outcomes by quartile categories (Q) of FT 4 levels at baseline, overall and by sex and age at baseline. CHD mortality CHD events Hard CHD events b FT 4 quartile catetories No. events / Overall Q / ( ) Q / ( ) Q / ( ) Q / Women Q 1 91 / ( ) Q 2 83 / ( ) Q 3 91 / ( ) Q / Men Q / ( ) Q / ( ) Q / ( ) Q / Age <65 years Q 1 39 / ( ) Q 2 15 / ( ) Q 3 41 / ( ) Q 4 30 / Age years Q / ( ) Q / ( ) Q / ( ) Q / No. events / 703 / ( ) 552 / ( ) 642 / ( ) 678 / / ( ) 241 / ( ) 250 / ( ) 285 / / ( ) 311 / ( ) 392 / ( ) 393 / / ( ) 168 / ( ) 183 / ( ) 155 / / ( ) 348 / ( ) 398 / ( ) 441 / No. events / 220 / ( ) 196 / ( ) 237 / ( ) 243 / / ( ) 104 / ( ) 97 / ( ) 118 / / ( ) 92 / ( ) 140 / ( ) 125 / / ( ) 3 / ( ) 4 / ( ) 4 / / ( ) 163 / ( ) 188 / ( ) 181 / American Medical Association. All rights reserved. 9
10 Age 80 years Q 1 43 / ( ) 64 / ( ) 48 / ( ) Q 2 28 / ( ) 36 / ( ) 30 / ( ) Q 3 36 / ( ) 61 / ( ) 45 / ( ) Q 4 39 / / / Abbreviations: CHD, coronary heart disease; CI, confidence interval; FT 4, free thyroxine;, hazard ratio a adjusted for age, sex and smoking at baseline b CHD mortality or myocardial infarction 2015 American Medical Association. All rights reserved. 10
11 etable 7. Sensitivity analyses of the association of FT 4 with risk of CHD outcomes. s a of CHD outcomes per 1 pmol/l higher FT 4 level at baseline. CHD mortality CHD events Hard CHD events b No. events/ No. events/ No. events/ Main analysis 931 / 23, ( ) 2575 / 18, ( ) 896 / ( ) Excluding with FT 4 level outside the reference range 887 / 22, ( ) 2470 / 17, ( ) 825 / ( ) Excluding the first 2 years of follow-up 839 / 23, ( ) 2179 / 17, ( ) 684 / ( ) With adjustment for BMI 917 / 23, ( ) 2528 / 17, ( ) 881 / ( ) Excluding with diabetes 824 / 22, / 17, / ( ) Restricted to never-smokers 336 / 11, ( ) Restricted to cohorts with information on thyroid medication during follow-up Including with thyroid 551 / 12, medication during follow-up ( ) Excluding with thyroid medication during follow-up Restricted to cohorts that were identified through the systematic literature searches 533 / 11, ( ) 792 / 19, ( ) ( ) 974 / ( ) 1365 / ( ) 1318 / ( ) 2152 / 14, ( ) ( ) 350 / ( ) 896 / ( ) 858 / ( ) 516 / ( ) Excluding the SHIP cohort 905 / 21, ( ) NA NA Excluding the Whickham Survey and the Leiden 85-Plus Study 908 / 23, ( ) 2539 / 17, ( ) 866 / ( ) Abbreviations: BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; FT 4, free thyroxine;, hazard ratio; NA, not applicable a adjusted for age, sex and smoking at baseline unless otherwise noted b CHD mortality or myocardial infarction 2015 American Medical Association. All rights reserved. 11
12 etable 8. Sensitivity analyses of the association of FT 4 quartile categories with risk of CHD outcomes. CHD mortality CHD events Hard CHD events a FT 4 quartile categories b 95% CI b 95% CI b 95% CI Main analysis Q Q Q Excluding with FT 4 level outside the reference range Q Q Q Excluding the first 2 years of follow-up Q Q Q With adjustment for BMI Q Q Q Excluding with diabetes Q Q Q Restricted to never-smokers Q Q Q Restricted to cohorts with information on thyroid medication during follow-up Including with thyroid medication during follow-up Q Q Q Excluding with thyroid medication during follow-up Q American Medical Association. All rights reserved. 12
13 Q Q Restricted to cohorts that were identified through the systematic literature searches Q Q Q Excluding the SHIP cohort Q Q Q Q Reference NA NA With adjustment for systolic blood pressure and total serum cholesterol Q Q Q Excluding the Whickham Survey and the Leiden 85-Plus Study Q Q Q Abbreviations: BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; FT 4, free thyroxine;, hazard ratio; NA, not applicable a CHD mortality or myocardial infarction b adjusted for age, sex and smoking at baseline unless otherwise noted 2015 American Medical Association. All rights reserved. 13
14 efigure. Hazard ratios (s) of coronary heart disease (CHD) mortality (A), a first-time CHD event (B) and a first-time hard CHD event (C) per 1 pmol/l higher free thyroxine (FT 4 ) level at baseline, adjusted for age, sex and smoking at baseline American Medical Association. All rights reserved. 14
15 The squares represent s from each cohort, and the lines represent 95% confidence intervals (CIs). The diamonds represent pooled s (with 95% CIs) from random-effects (D+L Overall) and fixed-effect (I-V Overall) meta-analysis American Medical Association. All rights reserved. 15
Supplementary Online Material
Supplementary Online Material Collet T-H, Gussekloo J, Bauer DC, et al; Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med.
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationSupplementary Online Content
Supplementary Online Content Blum MR, Bauer DC, Collet TH; et al. thyroid dysfunction and fracture risk: a meta-analysis. JAMA. doi: 10.1001/jama.2015.5161 emethods. Study Quality Assessment etable 1.
More informationSupplementary Online Content
Supplementary Online Content Li S, Chiuve SE, Flint A, et al. Better diet quality and decreased mortality among myocardial infarction survivors. JAMA Intern Med. Published online September 2, 2013. doi:10.1001/jamainternmed.2013.9768.
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationSupplementary Online Content
Supplementary Online Content McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol.
More informationRecords after duplicates removed (n = 2274) Records screened (n = 2274) Full-text articles assessed for eligibility (n = 16)
Supplemental Figure 1 Adapted from Prisma Flow Chart Records identified through database searching (n = 3093) Additional records identified through other sources (n = 2) Records after duplicates removed
More informationSupplementary Online Content
Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationEpidemiologic Measure of Association
Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationSupplementary Online Content
Supplementary Online Content Schnabel RB, Aspelund T, Li G, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med. 2010;170(21):1909-1917. eappendix.
More informationEuroPrevent 2010 Fatal versus total events in risk assessment models
EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the
More informationSupplementary Online Content
Supplementary Online Content Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in cardiology practices
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationThe Framingham Risk Score (FRS) is widely recommended
C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore
More informationSupplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
More informationSupplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationThis supplementary material has been provided by the authors to give readers
Supplementary Online Content LI D, Radulescu A, Shrestha RT, et al. Association of biotin ingestion with performance of hormone and nonhormone assays in healthy adults. JAMA. doi:1.11/jama.217.1375 efigure
More informationPopulation models of health impact of combination polypharmacy
Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067
More informationThe Whitehall II study originally comprised 10,308 (3413 women) individuals who, at
Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.
More informationGlycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men:
Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men: The Kuopio Ischaemic Heart Disease Risk Factor Study Jaakko Mursu, Jyrki K. Virtanen, Tiina H. Rissanen,
More informationORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease
ORIGINAL INVESTIGATION Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Lynn E. Eberly, PhD; Jeremiah Stamler, MD; James D. Neaton, PhD; for the Multiple
More informationCARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS
CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION by PAUL E. DRAWZ, MD, MHS Submitted in partial fulfillment of the requirements for the degree of Master
More informationSupplementary Online Content
Supplementary Online Content Wolters FJ, Li L, Gutnikov SA, Mehta Z, Rothwell PM. Medical attention seeking after transient ischemic attack and minor stroke in relation to the UK Face, Arm, Speech, Time
More informationSupplementary Online Content
Supplementary Online Content Irish AB, Viecelli AK, Hawley CM, et al; for the Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group.
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationSupplementary Online Content
Supplementary Online Content Sjöström L, Peltonen M, Jacobson P, et al. Association bariatric surgery with long-term remission type 2 diabetes and with microvascular and macrovascular complications. JAMA.
More informationSupplementary Online Content
Supplementary Online Content Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intimamedia thickness measurements in cardiovascular risk prediction. JAMA. doi:10.1001/jama.2012.9630. etable
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationManifestations and Survival in Coronary Heart Disease
From the Department of Emergency and Cardiovascular Medicine, Sahlgrenska University Hospital/Östra, Institute of Medicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Manifestations
More informationSupplementary Online Content
Supplementary Online Content Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals.
More informationSupplementary Online Content
Supplementary Online Content Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic
More informationPrediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal
Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal Koju R, Gurung R, Pant P, Humagain S, Yogol CM, Koju A, Manandhar K, Karmacharya B, Bedi TRS Address for Correspondence:
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationOrthostatic hypotension is common in elderly people 1 4
CLINICAL INVESTIGATIONS Orthostatic Hypotension and Risk of Cardiovascular Disease in Elderly People: The Rotterdam Study Germaine C. Verwoert, w Francesco U. S. Mattace-Raso, MD, PhD, w Albert Hofman,
More informationSupplementary Online Content
Supplementary Online Content Lewington S, Lacey B, Clarke R, et al; China Kadoorie Biobank Consortium. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern
More informationTEN-YEAR ABSOLUTE RISK ESTImates
ORIGINAL CONTRIBUTION CLINICIAN S CORNER Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Scan for Author Video Interview John T. Wilkins, MD, MS Hongyan Ning, MD, MS Jarett Berry, MD,
More informationAtherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke
«L Europe de la santé au service des patients» 13-14 October 2008 - Institut Pasteur Paris Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke Simona Giampaoli National Centre of
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationAll Discovered Death Outcome Detail (Form 124/120)
This file includes all reported deaths regardless of consent. ID WHI Common ID Col#1 DEATHALL All Discovered Death Col#2 Any report of death, regardless of consent status. 0 No 106,931 66.1 1 Yes 54,877
More informationFramingham Heart Study Longitudinal Data Documentation
Framingham Heart Study Longitudinal Data Documentation The Framingham Heart Study is a long term prospective study of the etiology of cardiovascular disease among a population of free living subjects in
More informationThe Impact of Diabetes Mellitus and Prior Myocardial Infarction on Mortality From All Causes and From Coronary Heart Disease in Men
Journal of the American College of Cardiology Vol. 40, No. 5, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02044-2
More informationNon-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
Diabetologia (2011) 54:73 77 DOI 10.1007/s00125-010-1945-z SHORT COMMUNICATION Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus S. van Dieren & U. Nöthlings & Y.
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationSmoking and atherosclerotic cardiovascular disease in women with lower levels of serum cholesterol
Atherosclerosis 190 (2007) 306 312 Smoking and atherosclerotic cardiovascular disease in women with lower levels of serum cholesterol Sun Ha Jee a,b,c,, Jungyong Park b, Inho Jo d, Jakyoung Lee a,b, Soojin
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More informationHeart Disease and Stroke Statistics 2010 Update. 2009, American Heart Association. All rights reserved.
Heart Disease and Stroke Statistics 21 Update Questions on statistics? mailto:nancy.haase@heart.org Audio-visual questions? mailto:david.brentz@heart.org Please keep the red wave and logo attached to these
More informationSUPPLEMENTARY DATA. Table of Contents
Table of Contents Supplemental Figure S1. Kaiser Permanente Diabetes Registry Patient Flow Diagram Supplemental Table S1. Diagnostic and procedure codes and frequency of events during follow-up for outcomes
More informationThyroid Dysfunction Associated with Coronary Heart Disease Barghchi E and Azizi F.
Is Thyroid Dysfunction Associated with Coronary Heart Disease? Elaheh Barghchi 1*, Fereidoun Azizi 2 1 Endocrinologist, Internal Medicine, Department of Endocrinology, University of Medical Sciences, Mashhad,
More informationAuthor Manuscript Faculty of Biology and Medicine Publication
Serveur Académique Lausannois SERVAL serval.unil.ch Author Manuscript Faculty of Biology and Medicine Publication This paper has been peer-reviewed but dos not include the final publisher proof-corrections
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationSeveral prospective studies have reported inverse relationships
Occurrence and Prognostic Significance of Ventricular Arrhythmia Is Related to Pulmonary Function A Study From Men Born in 1914, Malmö, Sweden Gunnar Engström, MD, PhD; Per Wollmer, MD, PhD; Bo Hedblad,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Supplemental Table 1. Distribution of Participants Characteristics by Treatment Group at Baseline - The Vitamin D and calcium (CaD) Trial of the Women s Health Initiative (WHI) Study,
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2014 June 24.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2013 June 24; 173(12): 1150 1151. doi:10.1001/jamainternmed.2013.910. SSRI Use, Depression and Long-Term Outcomes
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationBlood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan.
Blood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan. Manabu Izumi, Kazuo Suzuki, Tetsuya Sakamoto and Masato Hayashi Jichi Medical University
More informationSupplementary Online Content
Supplementary Online Content Khera R, Dharmarajan K, Wang Y, et al. Association of the hospital readmissions reduction program with mortality during and after hospitalization for acute myocardial infarction,
More informationSecondary Prevention of Coronary Heart Disease in Primary Health Care
& Secondary Prevention of Coronary Heart Disease in Primary Health Care Olivera Batić-Mujanović¹*, Muharem Zildžić², Azijada Beganlić¹ 1. House of Health Tuzla, Family Medicine Teaching Center, Albina
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationSupplementary Online Content
Supplementary Online Content Basaria S, Harman SM, Travison TG, et al. The effects of testosterone administration for three years on subclinical atherosclerosis progression in older men with low or low
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationSupplementary Online Content
Supplementary Online Content The Premenopausal Breast Cancer Collaborative Group. Association body mass index and age with premenopausal breast cancer risk in premenopausal women. JAMA Oncol. Published
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationRepeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group
Repeat ischaemic heart disease audit of primary care patients (2002-2003): Comparisons by age, sex and ethnic group Baseline-repeat ischaemic heart disease audit of primary care patients: a comparison
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Moran A, Zhao D, Gu D, et al. The Future Impact of Population
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationFatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins
Fatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins A Population-Based Prospective Cohort Study Gunnar Engström, MD; Bo Hedblad, MD; Lars Stavenow, MD; Patrik Tydén,
More information334 QOL QOL QOL QOL QOL T S % 35 60% QOL QUIK QUIK QUIK 4) QOL QOL 0 1 ο 3 4 ο 9 10ο19 20ο Q
Vol. 13 No. 2 2003 333 339 Λ1 QOL 4 50 QUIK171835 35 1 QUIK 2 QOL QUIK 3 QUIK QUIK QOL QOL DRG/PPS 1) 2) 3) QOL Λ1 769-0101 2396-15 333 334 QOL QOL QOL QOL QOL 1 2001 5 2001 10 6 T S 17 18 6 7 5 35 67%
More informationIschaemic heart disease (IHD) is the leading
Ischaemic heart disease (IHD) is the leading cause of death in economically developed countries and is rapidly assuming serious dimensions in developing countries. It is expected to be the single most
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationSupplementary Online Content
Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationRisk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
Diabetologia (2006) 49: 930 936 DOI 10.1007/s00125-006-0176-9 ARTICLE J. M. M. Evans. S. A. Ogston. A. Emslie-Smith. A. D. Morris Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes:
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More information